Retrieve available abstracts of 46 articles: HTML format
Single Articles
May 2025
KIM N, Kim YN, Lee K, Park E, et al Genomic Profiling in Patients with Endometrial Cancer by Deep Sequencing of
Vaginal Swabs and Plasma.
Clin Cancer Res. 2025 May 13. doi: 10.1158/1078-0432.CCR-24-4263. PubMedAbstract available
CHUI MH, Kang EY, Kahn RM, Chiang S, et al Clinicopathologic Features, Molecular Landscape, and Prognostic Implications of
Ovarian Low-Grade Serous Tumors with Histologic Transformation.
Clin Cancer Res. 2025 May 6. doi: 10.1158/1078-0432.CCR-24-3168. PubMedAbstract available
April 2025
KAAKS R, Cooley V, Mukama T, Teras LR, et al A Prospective Study Consortium for the Discovery and Validation of Early
Detection Markers for Ovarian Cancer ("PREDICT") - Baseline findings for CA125.
Clin Cancer Res. 2025 Apr 14. doi: 10.1158/1078-0432.CCR-24-1845. PubMedAbstract available
LEE JM, Miller A, Rose PG, AlHilli M, et al Comparing durvalumab, olaparib, and cediranib monotherapy, combination therapy,
or chemotherapy in patients with platinum-resistant ovarian cancer with prior
bevacizumab: the phase II NRG-GY023 trial.
Clin Cancer Res. 2025 Apr 7. doi: 10.1158/1078-0432.CCR-24-3877. PubMedAbstract available
March 2025
COSCIA F, Nielsen AB, Weigert M, Watters K, et al A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer.
Clin Cancer Res. 2025 Mar 27. doi: 10.1158/1078-0432.CCR-24-1763. PubMedAbstract available
GARG V, Oza AM Precision Endocrine Therapy in Endometrial Cancer: Has its time finally come?
Clin Cancer Res. 2025 Mar 21. doi: 10.1158/1078-0432.CCR-24-3905. PubMedAbstract available
BANERJEE S, Ghisoni E, Wolfer A, Ottevanger PB, et al Bevacizumab, atezolizumab and acetylsalicylic acid in recurrent,
platinum-resistant ovarian cancer: the EORTC 1508-GCG phase II study.
Clin Cancer Res. 2025 Mar 18. doi: 10.1158/1078-0432.CCR-24-3368. PubMedAbstract available
EERKENS AL, Esajas MD, Brummel K, Vledder A, et al Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade
Cervical Intraepithelial Neoplasia: A Phase II Trial.
Clin Cancer Res. 2025;31:1016-1026. PubMedAbstract available
PARK J, Joung JG, Lim MC, Lee J, et al Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for
Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized
Clinical Trial.
Clin Cancer Res. 2025 Mar 5. doi: 10.1158/1078-0432.CCR-24-3753. PubMedAbstract available
February 2025
MICHAELI O, Kim SY, Mitchell SG, Jongmans MCJ, et al Update on Cancer Screening in Children with Syndromes of Bone Lesions, Hereditary
Leiomyomatosis and Renal Cell Carcinoma Syndrome, and Other Rare Syndromes.
Clin Cancer Res. 2025;31:457-465. PubMedAbstract available
January 2025
ALQAISI HA, Cohn DE, Chern JY, Duska LR, et al Randomized phase II study of bevacizumab with weekly anetumab ravtansine or
weekly paclitaxel in platinum-resistant/refractory high grade ovarian cancer (NCI
trial).
Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-3128. PubMedAbstract available
CHAE YK, Corthell L, Patel SP, Edwards R, et al A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
SWOG S1609: Vulvar Cancers.
Clin Cancer Res. 2025;31:308-315. PubMedAbstract available
December 2024
SCHULTZ KAP, Nelson AT, Mallinger PHR, Harris AK, et al DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and
Recommended Surveillance Strategies.
Clin Cancer Res. 2024;30:5681-5692. PubMedAbstract available
SEO A, Xiao W, Gjyshi O, Yoshida-Court K, et al Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Cervical Cancer
Patients Undergoing Definitive Chemoradiation.
Clin Cancer Res. 2024 Dec 16. doi: 10.1158/1078-0432.CCR-24-2343. PubMedAbstract available
November 2024
GREEN AK, Zhou Q, Iasonos A, Zammarrelli WA, et al A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive
Advanced or Recurrent Endometrial Cancer.
Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1999. PubMedAbstract available
October 2024
BRAVO MELGAR J, Laoui D Chemotherapy Sparks Tertiary Lymphoid Structures in Metastatic Ovarian Cancer.
Clin Cancer Res. 2024 Oct 18. doi: 10.1158/1078-0432.CCR-24-2738. PubMedAbstract available
CHAE YK, Othus M, Patel SP, Wilkinson KJ, et al SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART):
Non-Epithelial Ovarian Cancer.
Clin Cancer Res. 2024 Oct 17. doi: 10.1158/1078-0432.CCR-24-0606. PubMedAbstract available
SOBERANIS PINA P, Clemens K, Bubie A, Grant B, et al Genomic landscape of circulating tumor DNA and real-world outcomes in advanced
endometrial cancer.
Clin Cancer Res. 2024 Oct 17. doi: 10.1158/1078-0432.CCR-24-2105. PubMedAbstract available
September 2024
JEON SH, You G, Park J, Chung Y, et al Anti-4-1BBxPDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T
Cells and Enhances the Efficacy of Anti-PD1 Blockade.
Clin Cancer Res. 2024;30:4155-4166. PubMedAbstract available
JOHANNET P, Friedman CF The intrauterine device: how to deploy this strategy in the molecular world?
Clin Cancer Res. 2024 Sep 10. doi: 10.1158/1078-0432.CCR-24-2034. PubMedAbstract available
August 2024
LANICKOVA T, Hensler M, Kasikova L, Vosahlikova S, et al Chemotherapy drives tertiary lymphoid structures that correlate with
ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer.
Clin Cancer Res. 2024 Aug 20. doi: 10.1158/1078-0432.CCR-24-1594. PubMedAbstract available
MCCORMICK A, Donoghue P, Dixon M, O'Sullivan R, et al Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting
in Resistance to Rucaparib.
Clin Cancer Res. 2024;30:3640. PubMed
BLANC-DURAND F, Ngoi NYL, Lim DG, Tan DSP, et al Unveiling Commonalities: Exploring Shared Characteristics in Clear Cell
Carcinomas of the Gynecologic Tract.
Clin Cancer Res. 2024 Aug 14. doi: 10.1158/1078-0432.CCR-24-1205. PubMedAbstract available
July 2024
RICHARDSON DL, Quintanilha JCF, Danziger N, Li G, et al Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2
and a scar-based HRD signature in real-world practice.
Clin Cancer Res. 2024 Jul 30. doi: 10.1158/1078-0432.CCR-24-1225. PubMedAbstract available
BONFILL-TEIXIDOR E, Neva-Alejo A, Arias A, Cuartas I, et al Cervical Cancer Evades the Host Immune System Through the Inhibition of Type I
Interferon and CXCL9 by LIF.
Clin Cancer Res. 2024 Jul 30. doi: 10.1158/1078-0432.CCR-24-0385. PubMedAbstract available
CORTES JE, Abruzzese E, Cardonick EH, Hernandez-Diaz S, et al Perspectives on drug development for the treatment of chronic myeloid leukemia in
pregnant patients and patients who are breastfeeding.
Clin Cancer Res. 2024 Jul 5. doi: 10.1158/1078-0432.CCR-24-0826. PubMedAbstract available
June 2024
BOWEN MB, Melendez B, Zhang Q, Yang RK, et al Long-term follow-up of levonorgestrel intrauterine device for atypical
hyperplasia and early endometrial cancer reveals relapse characterized by immune
exhaustion.
Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-24-0362. PubMedAbstract available
LEE HHY, Chow KL, Wong HS, Chong TY, et al Inhibition of aberrantly overexpressed Polo-like kinase 4 is a potential
effective treatment for DNA damage repair-deficient uterine leiomyosarcoma.
Clin Cancer Res. 2024 Jun 7. doi: 10.1158/1078-0432.CCR-23-3720. PubMedAbstract available
SANER FAM, Takahashi K, Budden T, Pandey A, et al Concurrent RB1 Loss and BRCA-Deficiency Predicts Enhanced Immunological Response
and Long-Term Survival in Tubo-Ovarian High-Grade Serous Carcinoma.
Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-23-3552. PubMedAbstract available
May 2024
CORBAUX P, Freyer G, Glehen O, You B, et al Intraperitoneal Nivolumab After Debulking Surgery and Hyperthermic
Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with
Expansion Cohort.
Clin Cancer Res. 2024 May 31. doi: 10.1158/1078-0432.CCR-24-0507. PubMedAbstract available
HADDAD TC, Suman VJ, Giridhar KV, Sideras K, et al Anastrozole dose escalation for optimal estrogen suppression in postmenopausal
early-stage breast cancer: A prospective trial.
Clin Cancer Res. 2024 May 16. doi: 10.1158/1078-0432.CCR-24-0341. PubMedAbstract available
SHETH SS, Oh JE, Bellone S, Siegel ER, et al Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine
versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions
(NCT02864147).
Clin Cancer Res. 2024;30:1768-1777. PubMedAbstract available
KHUSHMAN MM, Toboni MD, Xiu J, Manne U, et al Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse
Mismatch Repair Gene Alterations.
Clin Cancer Res. 2024;30:1906-1915. PubMedAbstract available
MIZUMOTO Y, Kyo S, Kiyono T, Takakura M, et al Editor's Note: Activation of NF-kappaB Is a Novel Target of KRAS-induced Endometrial
Carcinogenesis.
Clin Cancer Res. 2024;30:1995. PubMed
April 2024
LORENTZEN GM, Laniewski P, Cui H, Mahnert ND, et al Cervicovaginal metabolome and tumor characteristics for endometrial cancer
detection and risk stratification.
Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-2934. PubMedAbstract available
SON J, Zhang Y, Lin H, Mirallas O, et al Clinical and genomic landscape of RAS mutations in gynecologic cancers.
Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-2819. PubMedAbstract available
SIVARS L, Jylha C, Crona Guterstam Y, Zupancic M, et al Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for prognosis
and for early detection of relapse in locally advanced cervical cancer.
Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3941. PubMedAbstract available
NIEF CA, Hammer PM, Wang A, Charu V, et al Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.
Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3158. PubMedAbstract available
YANIZ-GALENDE E, Zeng Q, Grau-Bejar JF, Klein C, et al Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under
neoadjuvant chemotherapy.
Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3836. PubMedAbstract available
CHAMBERS L, Haight P, Chalif J, Mehra Y, et al Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to
Advance Endometrial Cancer and Cervical Cancer Immuno-Oncology Research.
Clin Cancer Res. 2024 Apr 25. doi: 10.1158/1078-0432.CCR-23-2570. PubMedAbstract available
VENEZIANI AC, Sneha S, Oza AM Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological Missile.
Clin Cancer Res. 2024;30:1434-1437. PubMedAbstract available
GITTO SB, Whicker M, Davies G, Kumar S, et al A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and
Platinum-Resistant Cancers with B7-H4 Expression.
Clin Cancer Res. 2024;30:1567-1581. PubMedAbstract available
March 2024
JAMIESON A, Sobral de Barros J, Cochrane DR, Douglas JM, et al Targeted and shallow whole genome sequencing identifies therapeutic opportunities
in p53abn endometrial cancers.
Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3689. PubMedAbstract available
KALOGERA E, Nevala WK, Finnes HD, Suman VJ, et al A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate
Therapy for Gynecologic Malignancies.
Clin Cancer Res. 2024 Mar 26. doi: 10.1158/1078-0432.CCR-23-3196. PubMedAbstract available
DERMAWAN JK, Chiang S, Singer S, Jadeja B, et al Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine
Leiomyosarcoma.
Clin Cancer Res. 2024 Mar 15. doi: 10.1158/1078-0432.CCR-24-0148. PubMedAbstract available
January 2024
TAN TJ, Sammons S, Im YH, She L, et al Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free
Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast
Cancer.
Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-2513. PubMedAbstract available